-
公开(公告)号:US20230047314A1
公开(公告)日:2023-02-16
申请号:US17952300
申请日:2022-09-25
Applicant: INTELGENX CORP.
Inventor: Nadine PAIEMENT , Rodolphe OBEID , Justin CONWAY , Billal TIR
IPC: A61K9/00 , A61K47/38 , A61K31/4985
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm
-
公开(公告)号:US20250120908A1
公开(公告)日:2025-04-17
申请号:US18928201
申请日:2024-10-28
Applicant: INTELGENX CORP.
Inventor: Nadine PAIEMENT , Rodolphe OBEID , Justin CONWAY , Billal TIR
IPC: A61K9/00 , A61K31/4985 , A61K47/38
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm
-
公开(公告)号:US20210022991A1
公开(公告)日:2021-01-28
申请号:US17063644
申请日:2020-10-05
Applicant: INTELGENX CORP.
Inventor: Nadine PAIEMENT , Rodolphe OBEID , Justin CONWAY , Billal TIR
IPC: A61K9/00 , A61K47/38 , A61K31/4985
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm
-
公开(公告)号:US20240245603A1
公开(公告)日:2024-07-25
申请号:US18275610
申请日:2022-02-07
Applicant: INTELGENX CORP.
Inventor: Billal TIR , Nadine PAIEMENT
IPC: A61K9/00 , A61K31/439
CPC classification number: A61K9/006 , A61K31/439
Abstract: An oral film dosage form includes a high loading of API designed to be administered in some form to a human subject and in some other form to an animal subject.
-
公开(公告)号:US20240189331A1
公开(公告)日:2024-06-13
申请号:US18276918
申请日:2022-02-14
Applicant: INTELGENX CORP.
Inventor: Mobarik BILAL , Billal TIR , Nadine PAIEMENT
IPC: A61K31/675 , A61K9/00 , A61K31/4045 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/38
CPC classification number: A61K31/675 , A61K9/006 , A61K31/4045 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/186 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/38
Abstract: The present disclosure relates to oral film formulations, which provide a tryptamine active agent. The disclosure more particularly relates to oral film formulations with improved buccal absorption of tryptamine active agents. The present disclosure also relates to formulations and methods for treatment of various symptoms in a patient, such as the treatment of mental health conditions.
-
6.
公开(公告)号:US20230404937A1
公开(公告)日:2023-12-21
申请号:US18208177
申请日:2023-06-09
Applicant: INTELGENX CORP.
Inventor: Billal TIR , Carolin MADWAR , Nadine PAIEMENT
CPC classification number: A61K9/7007 , A61K9/006 , A61K31/658 , A61K47/26 , A61K47/38 , A61K47/34 , A61K31/439
Abstract: Oral film formulations comprising at least one hydrophobic active agent; and a polymeric matrix at least partly composed of hydrophobic or insoluble excipients, or a combination thereof, to facilitate a controlled or sustained dissolution. Wherein when the oral film formulation has an unfavorable environment for fast dissolution, it exhibits partial disintegration within 1 to 10 minutes and a sustained rate of dissolution as confirmed by a disintegration test conducted in a limited volume petri dish, and wherein the film undergoes disintegration into smaller and smaller pieces.
-
公开(公告)号:US20230225965A1
公开(公告)日:2023-07-20
申请号:US18098683
申请日:2023-01-18
Applicant: INTELGENX CORP.
Inventor: Billal TIR , Nadine PAIEMENT
Abstract: Pharmaceutical compositions employing flavor entrapment to mitigate the unpleasant taste of active agents are described.
-
-
-
-
-
-